SEC investigating Illumina over acquisition of cancer test developer GrailIllumina's acquisition of cancer test developer Grail has also faced heavy scrutiny from antitrust regulators in the U.S. and European Union.[Collection]

Illumina's acquisition of cancer test developer Grail has also faced heavy scrutiny from antitrust regulators in the U.S. and European Union.https://www.cnbc.com/2023/08/11/sec-investigating-illumina-grail-acquisition.html